YB3.F Shin Nippon Biomedical Laboratories Ltd
- Market cap
- EUR 285M
- P/E
- 9.1x
- P/B
- 1.25x
- ROE
- 11.1%
- Dividend yield
- 4.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is YB3.F undervalued?
Graham numberYB3.F trades 28.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shin Nippon Biomedical Laboratories Ltd fundamental analysis
No fundamental analysis for Shin Nippon Biomedical Laboratories Ltd yet.
Shin Nippon Biomedical Laboratories Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shin Nippon Biomedical Laboratories Ltd
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activiti…
Full company profileShin Nippon Biomedical Laboratories Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shin Nippon Biomedical Laboratories Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.2B | 16.6B | 15.7B | 14.6B | 15.1B | 17.7B | 25.1B | 26.5B | 32.4B | 32.5B | 35.1B |
| Gross Profit | 4.36B | 5.20B | 6.18B | 7.62B | 7.55B | 9.69B | 13.0B | 14.3B | 17.0B | 16.2B | 17.5B |
| Operating Income | -1.79B | -697M | 830M | 2.23B | 2.53B | 4.20B | 5.25B | 4.16B | 2.99B | 2.65B | 3.11B |
| EBITDA | - | 339M | 3.39B | 4.53B | 5.55B | 9.49B | 9.49B | 8.98B | 8.83B | 9.97B | 6.42B |
| Net Income | -916M | -3.56B | 1.95B | 2.55B | 3.66B | 7.13B | 6.06B | 5.53B | 4.92B | 4.57B | 4.40B |
| EPS | -22 | -85 | 47 | 61 | 88 | 171 | 146 | 133 | 118 | 110 | 106 |
| Balance Sheet | |||||||||||
| Total Assets | 56.3B | 57.6B | 54.3B | 39.0B | 37.0B | 39.3B | 57.2B | 76.3B | 92.4B | 105B | 109B |
| Total Liabilities | 33.8B | 31.4B | 25.9B | 22.6B | 21.1B | 19.6B | 30.9B | 42.1B | 52.3B | 61.6B | 69.5B |
| Shareholders' Equity | 22.5B | 26.2B | 28.4B | 16.3B | 15.7B | 19.6B | 26.2B | 34.1B | 40.0B | 43.1B | 39.5B |
| Cash & Short-term Investments | 7.42B | 5.31B | 5.14B | 5.25B | 7.23B | 6.63B | 10.5B | 10.3B | 12.0B | 18.5B | 24.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -849M | 1.34B | 2.89B | 3.02B | 4.75B | 5.95B | 4.00B | 2.11B | 7.04B | 8.33B | - |
| Capital Expenditure | 789M | 1.01B | 1.07B | 1.15B | 1.07B | 1.54B | 4.84B | 8.61B | 10.9B | 5.34B | 0.00 |
| Free Cash Flow | - | 326M | 1.79B | 1.79B | 3.63B | 4.34B | -952M | -6.50B | -3.90B | 2.99B | - |
| Ratios | |||||||||||
| ROE | -4.1% | -13.6% | 6.9% | 15.7% | 23.3% | 36.4% | 23.1% | 16.2% | 12.3% | 10.6% | 11.1% |
| ROA | -1.6% | -6.2% | 3.6% | 6.5% | 9.9% | 18.1% | 10.6% | 7.2% | 5.3% | 4.3% | 4.0% |
| Net Profit Margin | -5.3% | -21.4% | 12.5% | 17.5% | 24.2% | 40.2% | 24.2% | 20.9% | 15.2% | 14.0% | 12.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shin Nippon Biomedical Laboratories Ltd dividends
- Dividend yield
- 4.00%
- Forward dividend
- 0.28 EUR
- Payout ratio
- 45.6%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 2.08B | 50 | 45.6% |
| 2025 | JPY 2.10B | 50 | 42.6% |
| 2024 | JPY 2.07B | 50 | 37.5% |
| 2023 | JPY 2.49B | 60 | 41.0% |
| 2022 | JPY 827M | 20 | 11.6% |
| 2021 | JPY 207M | 4.97 | 5.7% |
| 2020 | EUR 123M | 2.95 | 4.8% |
| 2019 | EUR 123M | 2.95 | 6.3% |
| 2018 | EUR 123M | 2.95 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 27, 2005.
Who owns Shin Nippon Biomedical Laboratories Ltd
- Insiders 51.64%
- Institutions 22.11%
- Public & others 26.25%
- Shares outstanding 41.6M
- Free float 19.7M
Shin Nippon Biomedical Laboratories Ltd company profile
- Company name
- Shin Nippon Biomedical Laboratories Ltd
- Ticker
- YB3.F
- ISIN
- JP3379950003
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,680
- Fiscal year end
- March
- Address
- 2438 Miyanoura-cho, Kagoshima, Japan, 891-1394
- Phone
- 81 9 9294 2600
- Website
- snbl.co.jp
About Shin Nippon Biomedical Laboratories Ltd
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels. In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.
Shin Nippon Biomedical Laboratories Ltd management
10- Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.Chairman, CEO, Fisheries Business Officer & Chief Health Officer · born 1958
- Mr. Ken Takanashi CPA, MBA.Vice Chairman & Head of U.S. Real Estate Business · born 1964
- Mr. Hideyuki HiramaPresident & Representative Director · born 1977
- Takashi IriyamaSMEO, Head of Financial, Mgmt Acc, Corporate Strategy Div & Deputy NHP ARC Manager · born 1968
- Toshiyuki IwataExecu Officer, Deputy GM of the TR Business Div (Res and Deve), and Dep Dir of Nasal Mucosal Vaccine
- Kyomi NagatoshiSME Officer, Head of Gene Affairs & Human Resources & Dire · born 1966
- Dr. Hideshi Tsusaki DVM Ph.D.EMD, Dir., Hd of Tech. Inf.,Overseas Sales, NHP ARC & Glbl Busi. Dev. and GM of E&A Sales · born 1967
- Mr. Eishi TsunozakiSenior MD & Director · born 1967
- Mr. Ichiro NagataSr. Executive VP, Head of CRO Business, Head of Hospitality Business & Director · born 1985
- Yukihiro KiyaSenior Executive Officer & Head of IT